Psychemedics (PMD) Stock Price, News & Analysis

Company Overview

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $2.46 to $2.77
• 50-Day Range: $2.32 to $3.21
• 52-Week Range: $1.50 to $3.25
• Volume: 113,627 shs
• Average Volume: 31,876 shs
• Market Capitalization: $16.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PMD Stock Analysis - Frequently Asked Questions

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $5.20 million for the quarter. Psychemedics had a negative net margin of 14.59% and a negative trailing twelve-month return on equity of 49.05%.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 6/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PMD
• CIK: 806517
• Web: www.psychemedics.com
• Phone: (978) 206-8220
• Fax: 978-264-9236
• Employees: 140
• Year Founded: 1985

Profitability

• EPS (Most Recent Fiscal Year): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.15 million
• Net Margins: -14.59%
• Pretax Margin: -14.55%
• Return on Equity: -49.05%
• Return on Assets: -27.26%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.59
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $22.10 million
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.15 per share
• Price / Book: 2.32

Miscellaneous

• Outstanding Shares: 6,110,000
• Free Float: 5,256,000
• Market Cap: $16.31 million
• Optionable: Not Optionable
• Beta: N/A